NMNikolaus R. McFarland

Nikolaus R. McFarland

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nikolaus R. McFarland has a total of 407 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Voice and Speech in Atypical Parkinsonian Disorders

    by Federico Rodriguez‐Porcel, Farwa Ali, Michiko Bruno, Heather Davis Cuevas, Rohit Dhall, Kylie Dunne‐Platero, Lawrence I. Golbe, Ihtsham Haq, Nicole Herndon, Lawrence S. Honig, et al.

    Background: Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics. Objectives: This review aims to characterize speech impairment in APDs, offer practical guidance for clinical evaluation, highlight the role of Speech‐Language pathologists (SLPs) in diagnosis and management, and outline current and emerging management strategies. Methods: A narrative review was conducted by the Diagnosis and Treatment Working Group of CurePSP's Centers of Care, integrating literature and clinical experience to summarize evaluation, diagnosis, and treatment of motor speech disorders in APDs. Results: Speech changes in APDs are often mixed dysarthrias with hypokinetic, spastic, and/or ataxic components, and may include apraxia of speech; these are frequently more severe and progress quicker than in Parkinson's disease. These features can assist in differential diagnosis and should prompt early referral to SLPs. Despite the high prevalence of speech and voice changes, comprehensive assessment of motor speech disorders is uncommon in neurology clinics. Current evidence regarding the efficacy of interventions is mixed. Digital acoustic analysis and neuromodulation offer promising directions for diagnosis and treatment. Conclusions: Early, collaborative management of motor speech impairment elevates care in APDs. Neurologists and SLPs must work together to improve recognition, diagnosis, and care. Future research should focus on objective biomarkers and personalized therapies to support communication, autonomy, and quality of life for individuals living with APDs.


  • Open Access

    Single-cell multiomics identifies both shared and unique features of immune dysfunction in Parkinson’s disease and inflammatory bowel disease colon, plasma and stool

    by MacKenzie L. Bolen, Marc Buendia, Ji Shi, Hannah Staley, Jennifer M. Kachergus, Philip A. Efron, Gwoncheol Park, Ravinder Nagpal, Stephan D. Alvarez, Qing-Shan Xue, et al.

    Parkinson’s disease (PD) is the fastest growing neurodegenerative disease in the world1. Gastrointestinal (GI) dysfunction can occur decades before motor impairments and in up to 80% of individuals living with PD2,3,4. We investigated peripheral relationships that may underlie environmental contributions to mechanisms along the gut-blood axis that contribute to PD pathogenesis. Single-cell multiomic spatial molecular imaging (SMI) of colonic tissue localized inflammatory injury within epithelial cells that appear to be associated with iron mishandling in both inflammatory bowel disease (IBD) and PD biosamples. We found that both the single-cell SMI of RNA and protein revealed parallel cross-modal dysregulation in the gut epithelium, in both IBD and PD biosamples. These data are accompanied by plasma (PD) and stool (IBD) protein depletion of CCL22. Our findings suggest iron mishandling along the gut barrier likely contributes to systemic inflammation, which may be the catalyst that primes circulating immune cells to body-first PD pathogenesis.


  • Open Access

    Aerobic exercise-induced changes in fluid biomarkers in Parkinson’s disease

    by Nijee S. Luthra, Niyati Mehta, Miranda J. Munoz, Giamila Fantuzzi, Guillaume Lamotte, Jacob M. Haus, Nikolaus R. McFarland, Malú G. Tansey, Paulina Gonzalez-Latapi, Gabriela Caraveo, et al.

    Parkinson’s disease (PD) is a neurodegenerative disease characterized by motor and non-motor symptoms that progressively deteriorate and for which there is no disease-modifying pharmacological treatment. Exercise is widely recommended for individuals with PD due to its potential neuroprotective benefits. However, the mechanisms underlying these exercise-induced effects in PD remain poorly understood. Analyzing fluid biomarkers responsive to exercise could offer valuable insights into the mechanisms by which exercise impacts PD and aid in optimizing exercise prescriptions for individuals with PD. This review explores exercise-responsive biomarkers categorized into three key groups—neurotrophic, inflammatory, and neuroendocrine markers. It highlights both well-validated biomarkers and candidates with promising potential. We also highlight key biomarkers linked to PD pathology, such as α-synuclein, and their potential connection to exercise based on current evidence. Comprehensive characterization of these biomarkers will advance our understanding of the biological effects of exercise in PD, enabling mechanism-based and objective measures to evaluate exercise response in future clinical trials and its impact on PD signs and symptoms.


  • Open Access

    Peripheral immune cell response to stimulation stratifies Parkinson’s disease progression from prodromal to clinical stages

    by Julian R. Mark, Ann M. Titus, Hannah A. Staley, Stephan Alvarez, Savanna Mahn, Nikolaus R. McFarland, Rebecca L. Wallings, Malú Gámez Tansey

    The motor stage of Parkinson’s disease (PD) can be preceded for years by a prodromal stage characterized by non-motor symptoms like REM sleep behavior disorder (RBD), hyposmia, and constipation. Here, we show that multiple stages of idiopathic PD, including the pre-motor prodromal stage, can be stratified according to the inflammatory responses to stimulation of peripheral blood mononuclear cells ex vivo. IFNγ stimulation of isolated monocytes reveals increased stimulation-dependent secretion of TNF, IL-1β, and IL-8 in prodromal PD relative to moderate stage PD. Additionally, T cells stimulated with CD3/CD28 co-stimulatory beads show diminished proinflammatory cytokine secretion in early-moderate PD relative to prodromal. Receiver operating characteristic curves demonstrate that several cytokines produced by stimulated monocytes show high predictive utility for distinguishing prodromal PD individuals from neurologically healthy controls. Moreover, immune stimulation reveals deficits in CD8 + T-cell mitochondrial health in moderate PD, with relative mitochondrial health in CD8 + T cells being positively correlated with stimulation-dependent secretion of IL-1β, IL-8, and IL-10 in T cells from prodromal PD subjects. Dysregulated mitochondrial health in immune cells may contribute to peripheral inflammation and PD progression, and ex vivo stimulation-based assays have the potential to reveal novel biomarkers for patient stratification and progression with immune endophenotypes.


  • Open Access

    Single-cell multiomics identifies both shared and unique features of immune dysfunction in Parkinson’s disease and inflammatory bowel disease colon, plasma and stool

    by MacKenzie L. Bolen, Marc Buendia, Ji Shi, Hannah Staley, Jennifer M. Kachergus, Philip A. Efron, Gwoncheol Park, Ravinder Nagpal, Stephan D. Alvarez, Qing-Shan Xue, et al.

    Parkinson’s disease (PD) is the fastest growing neurodegenerative disease in the world 1 . Gastrointestinal (GI) dysfunction can occur decades before motor impairments and in up to 80% of individuals living with PD 2,3,4 . We investigated peripheral relationships that may underlie mechanisms along the gut-blood axis that contribute to PD pathogenesis. Single-cell multiomic spatial molecular imaging (SMI) of colonic tissue localized inflammatory injury within epithelial cells that appear to be associated with iron mishandling in both inflammatory bowel disease (IBD) and PD biosamples. We found that both the single-cell SMI of RNA and protein revealed parallel cross-modal dysregulation in the gut epithelium, in both IBD and PD biosamples. These data are accompanied by plasma (PD) and stool (IBD) protein depletion of CCL22. Our findings suggest iron mishandling along the gut barrier likely contributes to systemic inflammation, which may be the catalyst that primes circulating immune cells to body-first PD pathogenesis.


  • Open Access

    Comparative analysis of Parkinson’s and inflammatory bowel disease gut microbiomes reveals shared butyrate-producing bacteria depletion

    by Maeve E. Krueger, Jake Sondag Boles, Zachary D. Simon, Stephan D. Alvarez, Nikolaus R. McFarland, Michael S. Okun, Ellen M. Zimmermann, Christopher E. Forsmark, Malú Gámez Tansey

    Epidemiological studies reveal that inflammatory bowel disease (IBD) is associated with an increased risk of Parkinson’s disease (PD). Gut dysbiosis has been documented in both PD and IBD, however it is currently unknown whether gut dysbiosis underlies the epidemiological association between both diseases. To identify shared and distinct features of the PD and IBD microbiome, we recruited 54 PD, 26 IBD, and 16 healthy control individuals and performed the first joint analysis of gut metagenomes. Larger, publicly available PD and IBD metagenomic datasets were also analyzed to validate and extend our findings. Depletions in short-chain fatty acid (SCFA)-producing bacteria, including Roseburia intestinalis, Faecalibacterium prausnitzii, Anaerostipes hadrus, and Eubacterium rectale, as well depletion in SCFA-synthesis pathways were detected across PD and IBD datasets, suggesting that depletion of these microbes in IBD may influence the risk for PD development.


  • Open Access

    Peripheral blood immune cells from individuals with Parkinson's disease or inflammatory bowel disease share deficits in iron storage and transport that are modulated by non-steroidal anti-inflammatory drugs

    by MacKenzie L. Bolen, Beatriz Nuñes Gomes, Blake Gill, Kelly B. Menees, Hannah Staley, Janna Jernigan, Nikolaus R. McFarland, Ellen M. Zimmermann, Christopher E. Forsmark, Malú Gámez Tansey


  • Open Access

    Peripheral immune cell response to stimulation stratifies Parkinson’s disease progression from prodromal to clinical stages

    by Julian R. Mark, Ann M. Titus, Hannah A. Staley, Stephan Alvarez, Savanna Mahn, Nikolaus R. McFarland, Rebecca L. Wallings, Malú Gámez Tansey

    The motor stage of idiopathic Parkinson’s disease (iPD) can be preceded for years by a prodromal stage characterized by non-motor symptoms like REM sleep behavior disorder (RBD). Here, we show that multiple stages of iPD, including the pre-motor prodromal stage, can be stratified according to the inflammatory and immunometabolic responses to stimulation of peripheral blood mononuclear cells ex vivo . We identified increased stimulation-dependent secretion of TNF, IL-1β, and IL-8 in monocytes from RBD patients and showed diminished proinflammatory cytokine secretion in monocytes and T cells in early and moderate stages of PD. Mechanistically, immune activation revealed deficits in CD8 + T-cell mitochondrial health in moderate PD, and relative mitochondrial health in CD8 + T cells was positively correlated with stimulation-dependent T-cell cytokine secretion across the PD spectrum. Dysregulated immunometabolism may drive peripheral inflammation and PD progression, and ex vivo stimulation-based assays have potential to reveal novel biomarkers for patient stratification and progression with immune endophenotypes.

  • Open Access

    A General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders

    by Michiko K. Bruno, Rohit Dhall, Antoine Duquette, Ihtsham U. Haq, Lawrence S. Honig, Guillaume Lamotte, Zoltan Mari, Nikolaus R. McFarland, Leila Montaser-Kouhsari, Federico Rodriguez-Porcel, et al.

    The most common four neurodegenerative atypical parkinsonian disorders (APDs) are progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal syndrome (CBS), and dementia with Lewy bodies (DLB). Their formal diagnostic criteria often require subspecialty experience to implement as designed and all require excluding competing diagnoses without clearly specifying how to do that. Validated diagnostic criteria are not available at all for many of the other common APDs, including normal pressure hydrocephalus (NPH), vascular parkinsonism (VP), or drug-induced parkinsonism (DIP). APDs also include conditions of structural, genetic, vascular, toxic/metabolic, infectious, and autoimmune origin. Their differential diagnosis can be challenging early in the course, if the presentation is atypical, or if a rare or non-neurodegenerative condition is present. This review equips community general neurologists to make an early provisional diagnosis before, or in place of, referral to a tertiary center. Early diagnosis would allay diagnostic uncertainty, allow prompt symptomatic management, provide disease-specific information and support resources, avoid further pointless testing and treatments, and create the possibility of trial referral. We address 64 APDs using one over-arching flow diagram and a series of detailed tables. Most instances of APDs can be diagnosed with a careful history and neurological exam, along with a non-contrast brain MRI. Additional diagnostic tests are rarely needed but are delineated where applicable. Our diagnostic algorithm encourages referral to a tertiary center whenever the general neurologist feels it would be in the patient's best interest. Our algorithm emphasizes that the diagnosis of APDs is an iterative process, refined with the appearance of new diagnostic features, availability of new technology, and advances in scientific understanding of the disorders. Clinicians' proposals for all diagnostic tests for the APDs, including repeat visits, should be discussed with patients and their families to ensure that the potential information to be gained aligns with their larger clinical goals. We designed this differential diagnostic algorithm for the APDs to enhance general neurologists' diagnostic skills and confidence and to help them address the less common or more ambiguous cases.


  • Open Access

    MHCII reduction is insufficient to protect mice from alpha-synuclein-induced degeneration and the Parkinson’s HLA locus exhibits epigenetic regulation

    by Elizabeth M Kline, Janna E Jernigan, Christopher D Scharer, Jeffrey Maurer, Sakeenah Hicks Sl, Mary K Herrick M, Rebecca L Wallings, Sean D Kelly, Jianjun Chang, Kelly B Menees, et al.

    Major histocompatibility complex class II (MHCII) molecules are antigen presentation proteins and increased in post-mortem Parkinson’s disease (PD) brain. Attempts to decrease MHCII expression have led to neuroprotection in PD mouse models. Our group reported that a SNP at rs3129882 in the MHCII gene Human leukocyte Antigen (HLA) DRA is associated with increased MHCII transcripts and surface protein and increased risk for late-onset idiopathic PD. We therefore hypothesized that decreased MHCII may mitigate dopaminergic degeneration. During an ongoing α-synuclein lesion, mice with MHCII reduction in systemic and brain innate immune cells (LysMCre+I-Ab fl/fl or CRE+) displayed brain T cell repertoire shifts and greater preservation of the dopaminergic phenotype in nigrostriatal terminals. Next, we investigated a human cohort to characterize the immunophenotype of subjects with and without the high-risk GG genotype at the rs3129882 SNP. We confirmed that the high-risk GG genotype is associated with peripheral changes in MHCII inducibility, frequency of CD4+ T cells, and differentially accessible chromatin regions within the MHCII locus. Although our mouse studies indicate that myeloid MHCII reduction coinciding with an intact adaptive immune system is insufficient to fully protect dopamine neurons from α-synuclein-induced degeneration, our data are consistent with the overwhelming evidence implicating antigen presentation in PD pathophysiology.